Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison The NETWORK investigators

Findings The number of patients reaching the primary end-point was 62 (12·3%) in the 2·5 mg twice daily group, 66 (12·9%) in the 5 mg twice daily group and 76 (14·7%) in the 10 mg twice daily group. Deaths in each group were 21 (4·2%), 17 (3·3%) and 15 (2·9%), respectively. There were no significant diVerences in the results between the three groups. The crude relative risk for the combined end-point in the 10 mg twice daily group compared to the 2·5 mg twice daily group was 1·20 (95% CI 0·88 to 1·64). Interpretation NETWORK did not demonstrate a relationship between dose of enalapril and clinical outcome in patients with heart failure selected from both primary care and hospital practice. (Eur Heart J 1998; 19: 481‐489)